MabVax Therapeutics Holdings (MBVX) Receives Daily Media Sentiment Rating of 0.06

News stories about MabVax Therapeutics Holdings (NASDAQ:MBVX) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MabVax Therapeutics Holdings earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.8834719911564 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

• BRIEF-Mabvax Therapeutics Holdings, Inc. Announces the closing of $1.3 million registered direct offering (reuters.com)
• MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
• MABVAX THERAPEUTICS HOLDINGS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) (4-traders.com)
• MabVax Therapeutics (MBVX) to Explore Strategic Alternatives; Closes $1.3M Direct Offering (streetinsider.com)

MabVax Therapeutics Holdings (MBVX) traded down 2.08% on Friday, hitting $0.47. 56,481 shares of the stock traded hands. MabVax Therapeutics Holdings has a 52 week low of $0.43 and a 52 week high of $6.05. The firm’s market capitalization is $4.96 million. The stock has a 50 day moving average of $0.76 and a 200 day moving average of $1.77.

MabVax Therapeutics Holdings (NASDAQ:MBVX) last announced its quarterly earnings results on Monday, August 14th. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by $0.78. Equities research analysts anticipate that MabVax Therapeutics Holdings will post ($2.91) earnings per share for the current year.

WARNING: “[[title]]” was first posted by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at [[permalink]].

MabVax Therapeutics Holdings Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.